Quadrant Capital Group’s Vaxcyte PCVX Stock Holding History

Quadrant Capital Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,862	Closed	-$108K	–	2184
2026 Q1	$108K	Hold	1,862	–	–	﹤0.01%	1459
2025 Q4	$85.9K	Buy	1,862 +6	+0.3%	+$268	﹤0.01%	1521
2025 Q3	$66.9K	Buy	+1,856	New	+$61.5K	﹤0.01%	1575
2025 Q2	–	Sell	-7	Closed	-$265	–	2234
2025 Q1	$265	Sell	7 -3	-30%	-$240	﹤0.01%	2703
2024 Q4	$819	Buy	+10	New	+$993	﹤0.01%	2603
2023 Q1	–	Sell	-27	Closed	-$1.29K	–	2771
2022 Q4	$1.29K	Buy	+27	New	+$1.06K	﹤0.01%	2498

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Quadrant Capital Group's PCVX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 1,862 shares — an estimated $108K sold.

Quadrant Capital Group first reported a position in PCVX in Q4 2022 and held it in 6 quarters. The position peaked at $108K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Quadrant Capital Group reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1,862 Vaxcyte shares in Q2 2026, an estimated $108K.
Quadrant Capital Group first reported a position in Vaxcyte in Q4 2022 and held it in 6 quarters.
Quadrant Capital Group's Vaxcyte position peaked at $108K in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.